by PharmacyChecker.com | Jun 7, 2011 | Drug Prices
In March of this year the FDA took the unusual step of allowing an “unapproved” compounded drug to remain on the market to explicitly make sure Americans could afford that product. That drug is hydroxyprogesterone caproate, branded by K-V Pharmaceuticals as Makena, the first FDA-approved drug to prevent the risk of preterm birth in certain women. Will more such government interventions continue in support of drug affordability?
According to the Wall Street Journal Blog,“Typically, whenever a drug is approved, pharmacy compounding isn’t allowed and the FDA acts to remove any unapproved drugs that might on be the U.S. market.” However, the FDA is allowing the compound to remain solely because of the outrageous cost for the brand-name product; Makena is priced at $1,500 per dose! Before Makena was approved, the same drug without the K-V branding and FDA stamp of approval cost between $10 – 20 per dose.
To the best of our knowledge, the FDA’s role does not include controlling prices to help Americans have access to the medication they need. However, that is precisely what the FDA did in the case of Makena. In our opinion, that’s also what the FDA does by not enforcing certain personal drug importation laws that, if enforced, would prevent Americans from affording needed medication. Currently, under its personal drug importation policy, the FDA has stated it does not take enforcement action against individuals who import non-controlled medicines, which are generally (and ironically) viewed as not FDA-approved even if they’re the exact same drug sold here, often due to labelling or pill color and shape differences between otherwise identical products. (more…)
Tagged with: Americans, Avanair Pharmaceuticals, Colcrys, Compound drugs, Drug Importation, FDA, FDA-approved, hydroxyprogesterone caproate, K-V Pharmaceuticals, lawmakers, Makena, non-controlled medicines, Not FDA-approved, Nuedexta, personal drug importation, Pharmaceutical Prices, policy, U.S. Government, URL Pharma, Wall Street Journal
by Gabriel Levitt, President, PharmacyChecker.com and Prescription Justice | May 31, 2011 | Drug Importation, Online Pharmacies
Last Thursday, the Senate Judiciary Committee unanimously passed S. 968, Preventing Real Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011, also known as the Protect IP Act. Its passage represents a real threat to Americans’ access to safe and affordable medications online and we hope that as the bill makes its way through the legislative process it will be amended appropriately.
Essentially, the bill will make it easier to crackdown on rogue pharmacy sites selling fake meds and not requiring a prescription, which is great; however, it will also encourage actions to block Americans’ access to reputable and affordable non-U.S. online pharmacies that sell genuine medication and require a prescription, which are a lifeline for uninsured Americans. That’s because of Section 5, which includes in its definition of “infringing sites” online pharmacies that sell medications to Americans that are not manufactured in a facility approved by the FDA. (more…)
Tagged with: Americans, Australia, Canada, cloture, Demand Progress, Electronic Frontier Foundation, Eli Lily, European Union, fake meds, FDA, First Amendment, GlaxoSmithKline, Google, legislation, Merck, Online Pharmacies, Pfizer, S.968, Senate Judiciary Committee, Senator Wyden, The Protect Intellectual Property Act, UK, United States
by PharmacyChecker.com | May 24, 2011 | Drug Prices, Saving Money on Prescription Drugs
Generic prescriptions are on the rise, as doctors are prescribing them, and pharmacies are filling them, now more than ever. We recently wrote that the percentage of generic scripts being dispensed rose to 78% last year. But the popularity for generics – attributed to the significantly lower price tag compared to brand name drugs – is expected to take on a whole new meaning, as the patents for some blockbuster brand name drugs expire this year; this is also known as the “Patent Cliff”.
The biggest prize, Pfizer’s Lipitor (for Cholesterol), the number one selling drug in the U.S., goes generic later this year (November 2011); and Plavix (a blood thinner) and Actos (for Diabetes) will follow (May 2012 and August 2012, respectively). As patents run out, these and other popular prescription drugs will be far more affordable in the U.S., since generic drug prices tend to be lower here than in other countries. (more…)
Tagged with: Actos, blood thinner, brand name drugs, Canada, Celebrex, Cholesterol, consumer guide, Costco.com, diabetes, generic prescriptions, Lipitor, Patent Cliff, Pfizer, Plavix, Seroquel, Simvastatin, U.S. pharmacies, United States, Zocor
by Gabriel Levitt, President, PharmacyChecker.com and Prescription Justice | May 17, 2011 | Online Pharmacies, Personal Drug Importation
A new post on RxRights.org explains how the National Association of Boards of Pharmacy (NABP)’s Internet Drug Outlet Identification Program wrongly misleads consumers and the media by tagging all non-U.S. online pharmacies that sell to Americans as “rogue.” Essentially, that program’s list includes dangerous rogue online pharmacies along with reputable online pharmacies that meet high standards of safety but are simply not based in the United States. American consumers should expect more from pharmacy regulatory authorities and deserve to be properly informed. By adding properly verified international online pharmacies to the list, NABP scares Americans away from safe and affordable sources of medication. RxRight.org alerts the public that NABP’s program was sponsored with a grant from the drug giant Pfizer.
The post also deconstructs the ridiculous notion that only “FDA-approved” drugs are safe. It explains that the same exact drug purchased from a Canadian pharmacy (or any non-U.S. pharmacy) that is sold in the United States is “Not FDA-approved.” How can that be if it’s the same drug? There are many reasons, but one primary reason is labeling. FDA-approved drugs include approval of the drug’s specific labeling. That means that virtually all drugs sold in Canada that are compositionally identical to those sold in the United States are not “FDA-approved” because their labeling is different (such as including information in French and English), but of course they are equally as safe.
PharmacyChecker.com applauds RxRights.org for exposing misinformation campaigns sponsored by the pharmaceutical industry meant to scare Americans away from safe and affordable online pharmacies, wrongly inform the media, and shape our nation’s laws and regulations.
Tagged with: Canada, Canadian pharmacies, drugs from canada, FDA-approved, National Associations of Boards of Pharmacy, Not FDA-approved, Online Pharmacies, Pfizer, rogue pharmacies, RxRights.org, United States
by Gabriel Levitt, President, PharmacyChecker.com and Prescription Justice | May 13, 2011 | Online Pharmacies, Online Pharmacy Verification Services
Today the New York Times reported that Google is setting aside $500 million to settle what is apparently an investigation into whether it knowingly allowed rogue online pharmacies to advertise in its ad programs. We at PharmacyChecker.com are mentioned in this article because from the summer of 2006 until February 2010, Google’s stated policy was that its pharmacy advertisers had to be approved by PharmacyChecker.com, meeting our high standards. Unfortunately, as we have previously reported, rogue online pharmacies that never applied to our program found a way to advertise on Google. We were never the gatekeepers for Google; that remained their job.
In February of 2010, likely due to pressure from the government investigation and perhaps the pharmaceutical industry, Google changed its policy to exclude all non-U.S. online pharmacies from advertising on Google in the United States. It stopped working with us, as we do not exclude reputable and safe Canadian and other international pharmacies. Google began working with the Verified Internet Pharmacy Practice Site (VIPPS) program, run by the National Association of Boards of Pharmacy, a program that is only open to U.S. pharmacies. After this change, rogue online pharmacies apparently continued to advertise on Google. In November of last year, to take a stronger stance against rogue online pharmacies, Google filed a lawsuit against rogue online pharmacies, holding them liable for violating its advertising policies.
It appears that the gate through which advertisers enter Google has swung from too open, allowing in pharmacies never approved by us or others, to now just open a crack, where many good pharmacies offering good prices can’t get in. The $500 million allocated for a settlement is probably going to keep that door nearly closed for a while, but we hope that it will eventually swing to a place where rogues are kept out and good players get in. In the meantime, we remain diligently checking and monitoring online pharmacies. You can find them on our ratings pages and you can check their prices too.
Tagged with: Google, investigation, rogue online pharmacies
by PharmacyChecker.com | May 12, 2011 | Drug Prices
Last summer we reported on the prohibitive costs of AIDS and H.I.V. drugs in America. Due to high drug prices, plus overcrowded and inefficient AIDS Drug Assistance Programs, individuals suffering from these diseases live in fear, not knowing if they will get the meds they need. Sadly, the problem has gotten worse.
A recent discussion on an AIDS/H.I.V. community web forum is what caught our attention. In that forum’s thread entitled “Links to Stop White House from Blocking Online Pharmacies”, outspoken members have voiced outrage over recent price hikes of critical HIV medications.
As reported by the AIDS and H.I.V. advocacy website and monthly magazine POZ.com, Gilead Sciences, a major manufacturer of AIDS and H.I.V. prescription drugs, has increased prices for its top HIV medications. “Atripla increased by 5.1 percent, and Truvada and Emtriva increased by 7.9 percent.” Comparing prices for these drugs at a local New York bricks and mortar pharmacy to licensed and verified foreign pharmacies, one finds substantial price discrepancies:
Drug Prices for a Three-Month Supply
[table “16” not found /]
(more…)
Tagged with: AIDS, AIDS Health Foundation, America, Atripla, Change.org, community web forum, Drug Prices, Emtriva, Florida, Gilead Sciences, Governor Rick Scott, H.I.V., Online Pharmacies, petition, Truvada, United States, White House
